Kailera Therapeutics (KLRA)
Develops injectable and oral obesity medicines outside Greater China under a Hengrui license.
$16.01
Pre-market+0.17 (+1.07%)
At close$15.84(−3.47%)
Something off on this page? Send us feedback.
EPSReportedEstimate
——————May '26Aug '26
Reported——————−$3,650.00−$1.09
Estimate——————−$0.78−$0.90
Surprise——————−470,867.7%−21.6%
RevenueReportedEstimate
——————May '26Aug '26
Reported————————
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | −$0.90 | −$1.09 | −21.6% |
| May 2026 | −$0.78 | −$3,650.00 | −470,867.7% |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | −$0.90 | −$1.09 | −21.6% | — | — | — | −3.3% |
| May 26, 2026 | −$0.78 | −$3,650.00 | −470,867.7% | — | — | — | +1.6% |